Screener
Iovance Biotherapeutics, Inc. IOVA Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Proceeds from the issuance of common stock under employee stock purchase plan | 861 | 669 |
| Proceeds from the issuance of common stock upon exercise of options | 26 | 15 |
| Proceeds from the issuance of common stock, net | 148,081 | 162,009 |
| Net cash provided by financing activities | 143,623 | 156,545 |
| Effect of foreign exchange rate changes | (337) | 1,247 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (52,285) | 16,360 |
| Cash, Cash Equivalents and Restricted Cash Beginning of Period | 169,058 | 122,053 |
| Cash, Cash Equivalents and Restricted Cash End of Period | $116,773 | $138,413 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s financing cash flow?
- Iovance Biotherapeutics, Inc. (IOVA) reported financing cash flow of $49.29M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s financing cash flow changed year-over-year?
- Iovance Biotherapeutics, Inc.'s financing cash flow increased by 272.5% year-over-year, from $13.23M to $49.29M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s financing cash flow has grown at a 5.9% compound annual growth rate (CAGR), from $239.27M to $300.77M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Iovance Biotherapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude